Rep. Lloyd Doggett Purchases Shares of Johnson & Johnson (NYSE:JNJ)

Representative Lloyd Doggett (D-Texas) recently bought shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on January 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in Johnson & Johnson stock on December 9th.

Representative Lloyd Doggett also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 12/18/2025.
• Purchased $1,001 – $15,000 in shares of CocaCola (NYSE:KO) on 12/15/2025.
• Purchased $1,001 – $15,000 in shares of PPG Industries (NYSE:PPG) on 12/12/2025.
• Purchased $1,001 – $15,000 in shares of International Business Machines (NYSE:IBM) on 12/12/2025.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $204.32 on Tuesday. The company has a 50 day simple moving average of $201.45 and a two-hundred day simple moving average of $183.45. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $215.18. The company has a market capitalization of $492.26 billion, a price-to-earnings ratio of 19.72, a P/E/G ratio of 2.13 and a beta of 0.34. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is 50.19%.

Analyst Upgrades and Downgrades

JNJ has been the subject of several analyst reports. Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target for the company in a report on Monday, October 20th. HSBC restated a “buy” rating and set a $240.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, December 10th. Wells Fargo & Company upped their target price on shares of Johnson & Johnson from $212.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Stifel Nicolaus increased their price target on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a report on Wednesday, October 15th. Finally, JPMorgan Chase & Co. raised their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Tuesday, September 16th. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $212.62.

Institutional Trading of Johnson & Johnson

Large investors have recently made changes to their positions in the stock. Abich Financial Wealth Management LLC acquired a new position in Johnson & Johnson during the 3rd quarter valued at about $26,000. Clayton Financial Group LLC purchased a new stake in shares of Johnson & Johnson during the third quarter worth about $28,000. Evolution Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson during the second quarter worth about $27,000. Semmax Financial Advisors Inc. increased its holdings in shares of Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after acquiring an additional 72 shares in the last quarter. Finally, Turning Point Benefit Group Inc. purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at approximately $41,000. 69.55% of the stock is currently owned by institutional investors.

About Representative Doggett

Lloyd Doggett (Democratic Party) is a member of the U.S. House, representing Texas’ 37th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Doggett (Democratic Party) is running for re-election to the U.S. House to represent Texas’ 37th Congressional District. He declared candidacy for the 2026 election.

Lloyd Doggett was born in Austin, Texas. Doggett graduated from Austin High School in 1964. He earned a B.A. from the University of Texas at Austin in 1967 and a J.D. from the University of Texas in 1970. Doggett’s career experience includes working as an adjunct professor with the University of Texas School of Law. In the 116th Congress, Doggett served on the House Ways & Means Committee, and he co-founded the House Prescription Drug Taskforce.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.